We bring you the latest news from the healthcare about the health care in the United Kingdom.

vrijdag 16 februari 2018

The Lancet: [Comment] Adjuvant therapy for women with high-risk endometrial carcinoma

[Comment] Adjuvant therapy for women with high-risk endometrial carcinoma
Identification of optimal therapy for patients with high-risk endometrial carcinoma has been frustrated by near-dichotomous paradigms of surgical treatment in the international community and a scarcity of level 1 data to inform adjuvant treatment. For example, at a meeting of the European Society for Medical Oncology–European Society of Gynaecological Oncology–European Society for Radiotherapy and Oncology Endometrial Consensus Conference Working Group, 14 recommendations were supported by level 1 or 2 evidence out of 50 nonsurgical treatment topics.
Read more

[Comment] BMI and outcomes in melanoma: more evidence for the obesity paradox
The association between increased body-mass index (BMI) and the risk of developing and dying from cancer has been recognised across a broad range of tumour types.1,2 The magnitude of this association is so great that in the USA obesity is considered to be the major preventable cause of cancer.3 However, data regarding the effect of obesity on the outcomes of patients undergoing cancer treatment is less clear. Several observational studies in different tumour types have shown that a moderately increased BMI (compared with an optimal BMI of 22·5 kg/m2) is associated with improved outcomes both around the time of treatment and in later years of follow-up for several cancers.
Read more

[Articles] Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis
Our results suggest that in patients with metastatic melanoma, obesity is associated with improved progression-free survival and overall survival compared with those outcomes in patients with normal BMI, and that this association is mainly seen in male patients treated with targeted or immune therapy. These results have implications for the design of future clinical trials for patients with metastatic melanoma and the magnitude of the benefit found supports further investigation of the underlying mechanism of these associations.
Read more

[News] Public Health England publishes e-cigarette review
On Feb 6, 2018, Public Health England published an independent review of the evidence on electronic cigarettes (e-cigarettes).
Read more

[News] Apalutamide shows efficacy in prostate cancer
The androgen receptor inhibitor apalutamide significantly improves metastasis-free survival in patients with non-metastatic castration-resistant prostate cancer, according to a recent study.
Read more